AMPH Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
183.9M
+7.4%
171.2M
-6.5%
183.1M
-4.6%
191.8M
+10.0%
174.4M
Cost of Revenue
90.4M
-10.3%
100.8M
+3.5%
97.4M
+4.6%
93.2M
+6.0%
87.9M
Gross Profit
93.5M
+32.9%
70.3M
-17.9%
85.7M
-13.2%
98.6M
+14.1%
86.5M
Operating Expenses
53.7M
-5.2%
56.7M
+13.2%
50.1M
-31.7%
73.3M
+65.5%
44.3M
R&D
22.2M
-17.1%
26.7M
+14.7%
23.3M
+4.3%
22.4M
+11.3%
20.1M
SG&A
31.6M
+5.4%
30.0M
+12.0%
26.8M
-47.5%
51.0M
+110.4%
24.2M
Operating Income
39.7M
+191.5%
13.6M
-61.7%
35.6M
+40.6%
25.3M
-40.0%
42.2M
EBITDA
54.0M
+93.2%
28.0M
-44.0%
49.9M
+26.6%
39.4M
-30.5%
56.8M
Net Income
30.3M
+372.7%
6.4M
-73.7%
24.4M
+40.8%
17.4M
-44.1%
31.0M
EPS (Basic)
$0.69
+392.9%
$0.14
-73.6%
$0.53
+39.5%
$0.38
-42.4%
$0.66
EPS (Diluted)
$0.67
+378.6%
$0.14
-73.1%
$0.52
+40.5%
$0.37
-42.2%
$0.64
Shares (Diluted)
44.2M
-4.8%
46.5M
-1.5%
47.2M
-1.1%
47.7M
-0.9%
48.1M
Amphastar Pharmaceuticals (AMPH) โ€” Financials